Gut Microbiomes in HD
ConditionHuntington Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Central Florida
About this trial
The purpose of this study is to find out if there is a connection between the naturally occurring bacteria in our bodies and the progression of Huntington disease. The investigators are trying to determine if patients who are diagnosed with adult-onset HD and who exhibit a rapid rate of disease progression have unique populations of bacteria in their gut as compared to patients with slower progression.
Eligibility criteria
Qualifiers
18 years or older
Provide informed consent
Able to read and speak English
Agree to comply with study procedures
Disqualifiers
CAG repeat length ≥ 60 to exclude participants with juvenile onset HD.
CAG repeat length 36 - 39 to exclude participants with reduced penetrance. As this is a pilot study, we are primarily interested in participants with typical HD characteristics.
UHDRS Functional Capacity stage ≥ 4 to exclude late-stage HD patients who may be institutionalized and receive nutrition through a feeding tube.
System antibiotics, antifungals, antivirals, or anti-parasitics (intravenous, intramuscular, or oral)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
36 Participants
are grouped into 3 trial groupsSponsors and collaborators
University of Central Florida
Lead sponsor
University of South Florida
Collaborator
Source ClinicalTrials.gov